Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections

Research output: Contribution to journal › Review › Research › peer-review

Standard

Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. / Zhang, Li; Bera, Hriday; Wang, Hengzhuang; Wang, Junwei; Guo, Yi; Shi, Changzhi; Cun, Dongmei; Moser, Claus; Høiby, Niels; Yang, Mingshi.

In: International Journal of Pharmaceutics, Vol. 616, 121507, 2022.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Zhang, L, Bera, H, Wang, H, Wang, J, Guo, Y, Shi, C, Cun, D, Moser, C, Høiby, N & Yang, M 2022, 'Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections', International Journal of Pharmaceutics, vol. 616, 121507. https://doi.org/10.1016/j.ijpharm.2022.121507

APA

Zhang, L., Bera, H., Wang, H., Wang, J., Guo, Y., Shi, C., Cun, D., Moser, C., Høiby, N., & Yang, M. (2022). Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. International Journal of Pharmaceutics, 616, [121507]. https://doi.org/10.1016/j.ijpharm.2022.121507

Vancouver

Zhang L, Bera H, Wang H, Wang J, Guo Y, Shi C et al. Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. International Journal of Pharmaceutics. 2022;616. 121507. https://doi.org/10.1016/j.ijpharm.2022.121507

Author

Zhang, Li ; Bera, Hriday ; Wang, Hengzhuang ; Wang, Junwei ; Guo, Yi ; Shi, Changzhi ; Cun, Dongmei ; Moser, Claus ; Høiby, Niels ; Yang, Mingshi. / Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections. In: International Journal of Pharmaceutics. 2022 ; Vol. 616.

Bibtex

@article{b398cfde4b46492cbb9c8f57c59ff9af,
title = "Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections",
abstract = "Respiratory infections are one of the major global health problems. Among them, chronic respiratory infections caused by biofilm formation are difficult to treat because of both drug tolerance and poor drug penetration into the complex biofilm structure. A major part of the current research on combating respiratory biofilm infections have been focused on destroying the matrix of extracellular polymeric substance and eDNA of the biofilm or promoting the penetration of antibiotics through the extracellular polymeric substance via delivery technologies in order to kill the bacteria inside. There are also experimental data showing that certain inhaled antibiotics with simple formulations can effectively penetrate EPS to kill surficially located bacteria and centrally located dormant bacteria or persisters. This article aims to review recent advances in the pharmaceutical strategies for combating respiratory biofilm infections with a focus on nanotechnology-based drug delivery approaches. The formation and characteristics of bacterial biofilm infections in the airway mucus are presented, which is followed by a brief review on the current clinical approaches to treat respiratory biofilm infections by surgical removal and antimicrobial therapy, and also the emerging clinical treatment approaches. The current combination of antibiotics and non-antibiotic adjuvants to combat respiratory biofilm infections are also discussed.",
keywords = "Antimicrobial therapy, Biofilm infections, Combination therapy, Inhalation therapy, Nanotechnology-based drug delivery systems, P. aeruginosa, Respiratory infections",
author = "Li Zhang and Hriday Bera and Hengzhuang Wang and Junwei Wang and Yi Guo and Changzhi Shi and Dongmei Cun and Claus Moser and Niels H{\o}iby and Mingshi Yang",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",
year = "2022",
doi = "10.1016/j.ijpharm.2022.121507",
language = "English",
volume = "616",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Combination and nanotechnology based pharmaceutical strategies for combating respiratory bacterial biofilm infections

AU - Zhang, Li

AU - Bera, Hriday

AU - Wang, Hengzhuang

AU - Wang, Junwei

AU - Guo, Yi

AU - Shi, Changzhi

AU - Cun, Dongmei

AU - Moser, Claus

AU - Høiby, Niels

AU - Yang, Mingshi

N1 - Publisher Copyright: © 2022 Elsevier B.V.

PY - 2022

Y1 - 2022

N2 - Respiratory infections are one of the major global health problems. Among them, chronic respiratory infections caused by biofilm formation are difficult to treat because of both drug tolerance and poor drug penetration into the complex biofilm structure. A major part of the current research on combating respiratory biofilm infections have been focused on destroying the matrix of extracellular polymeric substance and eDNA of the biofilm or promoting the penetration of antibiotics through the extracellular polymeric substance via delivery technologies in order to kill the bacteria inside. There are also experimental data showing that certain inhaled antibiotics with simple formulations can effectively penetrate EPS to kill surficially located bacteria and centrally located dormant bacteria or persisters. This article aims to review recent advances in the pharmaceutical strategies for combating respiratory biofilm infections with a focus on nanotechnology-based drug delivery approaches. The formation and characteristics of bacterial biofilm infections in the airway mucus are presented, which is followed by a brief review on the current clinical approaches to treat respiratory biofilm infections by surgical removal and antimicrobial therapy, and also the emerging clinical treatment approaches. The current combination of antibiotics and non-antibiotic adjuvants to combat respiratory biofilm infections are also discussed.

AB - Respiratory infections are one of the major global health problems. Among them, chronic respiratory infections caused by biofilm formation are difficult to treat because of both drug tolerance and poor drug penetration into the complex biofilm structure. A major part of the current research on combating respiratory biofilm infections have been focused on destroying the matrix of extracellular polymeric substance and eDNA of the biofilm or promoting the penetration of antibiotics through the extracellular polymeric substance via delivery technologies in order to kill the bacteria inside. There are also experimental data showing that certain inhaled antibiotics with simple formulations can effectively penetrate EPS to kill surficially located bacteria and centrally located dormant bacteria or persisters. This article aims to review recent advances in the pharmaceutical strategies for combating respiratory biofilm infections with a focus on nanotechnology-based drug delivery approaches. The formation and characteristics of bacterial biofilm infections in the airway mucus are presented, which is followed by a brief review on the current clinical approaches to treat respiratory biofilm infections by surgical removal and antimicrobial therapy, and also the emerging clinical treatment approaches. The current combination of antibiotics and non-antibiotic adjuvants to combat respiratory biofilm infections are also discussed.

KW - Antimicrobial therapy

KW - Biofilm infections

KW - Combination therapy

KW - Inhalation therapy

KW - Nanotechnology-based drug delivery systems

KW - P. aeruginosa

KW - Respiratory infections

U2 - 10.1016/j.ijpharm.2022.121507

DO - 10.1016/j.ijpharm.2022.121507

M3 - Review

C2 - 35085729

AN - SCOPUS:85123865181

VL - 616

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

M1 - 121507

ER -

ID: 291603832